Amplia Therapeutics ( ) has provided an announcement. Amplia Therapeutics has released CEO Chris Burns’ presentation delivered at the Canaccord Genuity Drug and Device Conferenc ...
A new review in Advanced Cancer Research details how post-translational modifications regulate KRAS localization, activity, ...
A preclinical study shows that combining KRASG12D inhibition with CTLA-4 blockade dismantles a TGF-beta-driven regulatory T ...
Revolution Medicines’ stock slid 6.3% Thursday after newly released FDA review documents sparked investor unease around ...
Revolution Medicines (NDQ:RVMD), the most advanced company with an RAS inhibiting technology, is bringing the first drug based off its technology ...
Preclinical package also shows more than 2.5-fold survival extension in advanced PDAC models; Company contrasts a non-RAS, ...
A new preclinical study reveals that KRAS-mutant gastric adenocarcinoma fosters a TGF-beta-dependent immunosuppressive tumour ...
In adults with T2D, moderate CV risk, and albuminuria, receipt of GLP-1 RAs or SGLT-2 inhibitors slows kidney function decline.
RASONQUE Plus Zoldonrasib in First-Line RAS G12D PDAC / cancer, cancer care, Cancer research, cancer treatment, ...
FDA grants TRE-515 Fast Track status with KRAS G12C inhibitors for previously treated NSCLC. See what the designation means for development and review.
RAS G12D is the most common RAS variant in PDAC,” said Alan Sandler, M.D., chief development officer of Revolution Medicines. “In preclinical studies, the combination of RAS (ON) multi-selective and ...
Big pharma bets on KRAS G12D as oncology race intensifies Drugmakers chase tough G12D target with degraders and pan-KRAS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results